Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva completed the acquisition of BioXcel's neuroscience assets, including worldwide rights to BXCL501, for $57.5 million upfront plus up to $67.5 million in contingent payments. BXCL501 is under FDA review as the first at-home sublingual treatment for acute agitation in schizophrenia or bipolar disorder; the deal also includes the approved in-hospital product IGALMI.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.